Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs.
Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.
The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce’s efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts’ Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.
Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce’s anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.
Company Details
- Employees
- 21
- Founded
- -
- Address
- L25, 1 Farrer Place, Sydney,nsw 2000,australia
- Phone
- +61 (2) 8075 4585
- ja****@****.com.au
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- recce.com.au
- Keywords
- Sepsis, Superbugs, Polymers, Biotech, Synthetic Polymers, Antibiotics, Global Health, Antibiotic Resistance, Clinical Trials, Blood Infections, Infectious Disease, FDA, ASX, Pharmaceuticals, Diabetic Foot Infections, Urinary Tract Infections.
- HQ
- Sydney, NSW
- Competitors
- Incannex Healthcare Inc, Neuren Pharmaceuticals Limited, Douglas Pharmaceuticals, Mayne Pharma, Telix Pharmaceuticals Limited, Botanix Pharmaceuticals, Lipa Pharmaceuticals Limited - 8 x Winner of the CMA High Quality Manufacturer of the Year Award, Acadia Pharmaceuticals Inc., AFT Pharmaceuticals, Clarity Pharmaceuticals.
Recce Pharmaceuticals Ltd Questions
Recce Pharmaceuticals Ltd's helpline number is +61 (2) 8075 4585
Recce Pharmaceuticals Ltd's website is recce.com.au
Recce Pharmaceuticals Ltd's LinkedIn profile is https://www.linkedin.com/company/reccepharmaceuticals
Recce Pharmaceuticals Ltd has
21 employees.
View email and phone details for 21
employees at Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd's industry is
Pharmaceutical Manufacturing
Recce Pharmaceuticals Ltd's top competitors are
Incannex Healthcare Inc,
Neuren Pharmaceuticals Limited,
Douglas Pharmaceuticals,
Mayne Pharma,
Telix Pharmaceuticals Limited,
Botanix Pharmaceuticals,
Lipa Pharmaceuticals Limited - 8 X Winner Of The Cma High Quality Manufacturer Of The Year Award,
Acadia Pharmaceuticals Inc.,
Aft Pharmaceuticals,
Clarity Pharmaceuticals.
Recce Pharmaceuticals Ltd's support email address is james.graham@recce.com.au
Recce Pharmaceuticals Ltd's categories are Pharmaceutical Manufacturing
Recce Pharmaceuticals Ltd's founding year is 2007
